P
38.46
1.07 (2.86%)
| 前收盘价格 | 37.39 |
| 收盘价格 | 37.50 |
| 成交量 | 648,870 |
| 平均成交量 (3个月) | 1,128,593 |
| 市值 | 2,139,758,208 |
| 价格/销量 (P/S) | 6.84 |
| 股市价格/股市净资产 (P/B) | 5.02 |
| 52周波幅 | |
| 利润日期 | 28 Oct 2025 |
| 营业毛利率 | -36.20% |
| 营业利益率 (TTM) | -39.67% |
| 稀释每股收益 (EPS TTM) | -1.69 |
| 季度收入增长率 (YOY) | 55.30% |
| 总债务/股东权益 (D/E MRQ) | 21.02% |
| 流动比率 (MRQ) | 8.95 |
| 营业现金流 (OCF TTM) | -83.91 M |
| 杠杆自由现金流 (LFCF TTM) | -58.77 M |
| 资产报酬率 (ROA TTM) | -13.36% |
| 股东权益报酬率 (ROE TTM) | -27.62% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 看跌 |
| Medical Devices (全球的) | 混合的 | 看跌 | |
| 股票 | PROCEPT BioRobotics Corporation | 看跌 | 看跌 |
AIStockmoo 评分
1.0
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 1.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.0 |
| 平均 | 1.00 |
|
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.22% |
| 机构持股比例 | 93.06% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 60.00 (Oppenheimer, 56.01%) | 购买 |
| 中 | 56.50 (46.91%) | |
| 低 | 50.00 (Truist Securities, 30.01%) | 购买 |
| 平均值 | 55.75 (44.96%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 38.13 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Truist Securities | 15 Oct 2025 | 50.00 (30.01%) | 购买 | 33.76 |
| Oppenheimer | 02 Sep 2025 | 60.00 (56.01%) | 购买 | 39.57 |
| Piper Sandler | 07 Aug 2025 | 55.00 (43.01%) | 购买 | 39.59 |
| Wells Fargo | 07 Aug 2025 | 58.00 (50.81%) | 购买 | 39.59 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合